AVBP vs GHRS: Which Stock Is the Better Buy?
ArriVent BioPharma, Inc. and GH Research PLC side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — AVBP vs GHRS, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| ArriVent BioPharma, Inc. (AVBP) | GH Research PLC (GHRS) | |
|---|---|---|
| Market cap | $1.4B | $1.4B |
| Revenue (latest FY) | $0 | $0 |
| Net income (latest FY) | $-166.31M | $-48.26M |
| Revenue growth (5y CAGR) | — | — |
| Net margin | — | — |
| Return on equity | -54.1% | -17.3% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | — | — |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full AVBP vs GHRS breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open AVBP's full financials → Open GHRS's full financials →More comparisons
Frequently asked questions
Which is bigger, AVBP or GHRS?
ArriVent BioPharma, Inc. is larger by market capitalization — $1.4B versus $1.4B.
Which grows faster, AVBP or GHRS?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.